Hans Preusting

Hans Preusting has a diverse range of work experience in the biotechnology and pharmaceutical industries. Hans currently serves as a Member of the Board at Mendus AB, a position they began in May 2021. Prior to this role, they were the CEO of Synerkine Pharma starting from July 2018. Hans also held the position of Chief Development Officer at DegenRx B.V. from December 2018.

In 2016, Hans Preusting worked as a DGA/Consultant at Explicatio4U B.V. for an unspecified duration. Hans also briefly owned their own consulting firm, PreuConsult, in the same year.

Hans Preusting has held significant roles at uniQure, starting as the VP, Business Development & Operations from August 2006 until April 2012. Hans later became the Chief Business Officer from January 2013 to December 2015. Additionally, they served as the Interim Chief Operating Officer from July 2013 to March 2014. Notably, uniQure is the successor of AMT, a gene therapy company.

Hans Preusting has also been involved in various supervisory and board member positions. Hans served as a Member of the Supervisory Board at DCprime bv from April 2019 to December 2020. Hans was a Supervisory Board Member at PharmaCell from April 2013 to May 2017. Moreover, they held the position of Chairman at the Nederlandse Biotechnologische Vereniging (NBV) from April 2009 to June 2013.

In terms of education, they completed an MBA from RSM Erasmus University from September 2009 to June 2011.

Hans Preusting completed their education in a chronological order. Hans first pursued their Bachelor of Science degree in Chemistry at the University of Groningen from 1981 to 1987. Following this, they pursued a doctoral degree in Biochemistry from the same institution from 1987 to 1992. Later, from 2009 to 2011, they attended the Rotterdam School of Management, Erasmus University, where they completed a Master of Business Administration (MBA) degree.